A randomised trial of epirubicin versus mitomycin C at the time of first recurrence in superficial bladder cancer
Not Applicable
Completed
- Conditions
- CancerBladder cancer
- Registration Number
- ISRCTN77353795
- Lead Sponsor
- Medical Research Council (MRC) (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 800
Inclusion Criteria
1. Newly-diagnosed superficial carcinoma of bladder suitable for complete endoscopic resection, limited to the bladder
2. World Health Organisation (WHO) status zero to two
3. Expected survival at least three years
4. No history of other malignant tumours, except non-melanomatous skin tumours, or carcinoma in-situ (CIN)
5. No untreated urinary tract infection (UTI)
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of epirubicin and mitomycin C in superficial bladder cancer recurrence treatment?
How does the efficacy of epirubicin versus mitomycin C compare to standard-of-care therapies for first recurrence superficial bladder cancer?
Which biomarkers predict response to epirubicin or mitomycin C in superficial bladder cancer recurrence patients?
What are the adverse event profiles and management strategies for epirubicin and mitomycin C in bladder cancer recurrence treatment?
Are there combination therapies involving epirubicin or mitomycin C that improve outcomes in superficial bladder cancer recurrence?